<SEC-DOCUMENT>0001104659-25-107806.txt : 20251106
<SEC-HEADER>0001104659-25-107806.hdr.sgml : 20251106
<ACCEPTANCE-DATETIME>20251106164341
ACCESSION NUMBER:		0001104659-25-107806
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20251104
FILED AS OF DATE:		20251106
DATE AS OF CHANGE:		20251106

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Rozek Elizabeth
		CENTRAL INDEX KEY:			0001975022
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41742
		FILM NUMBER:		251459182

	MAIL ADDRESS:	
		STREET 1:		SAGIMET BIOSCIENCES INC.
		STREET 2:		155 BOVET ROAD, SUITE 303
		CITY:			SAN MATEO
		STATE:			CA
		ZIP:			94402

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sagimet Biosciences Inc.
		CENTRAL INDEX KEY:			0001400118
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				205991472
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		155 BOVET RD., SUITE 303
		CITY:			SAN MATEO
		STATE:			CA
		ZIP:			94402
		BUSINESS PHONE:		(650) 561-8600

	MAIL ADDRESS:	
		STREET 1:		155 BOVET RD., SUITE 303
		CITY:			SAN MATEO
		STATE:			CA
		ZIP:			94402

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	3-V Biosciences, Inc.
		DATE OF NAME CHANGE:	20070521
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>tm2530509-1_4seq1.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-11-04</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001400118</issuerCik>
        <issuerName>Sagimet Biosciences Inc.</issuerName>
        <issuerTradingSymbol>SGMT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001975022</rptOwnerCik>
            <rptOwnerName>Rozek Elizabeth</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>SAGIMET BIOSCIENCES INC.</rptOwnerStreet1>
            <rptOwnerStreet2>155 BOVET ROAD, SUITE 303</rptOwnerStreet2>
            <rptOwnerCity>SAN MATEO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94402</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Legal &amp; Admin. Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Series A Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-11-04</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>9855</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>193581</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>7.61</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-11-04</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>13367</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-11-03</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Series A Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>13367</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>13367</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Represents restricted stock units (&quot;RSUs&quot;) granted in connection with the Reporting Person's promotion within the Company. Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following November 4, 2025, subject to the Reporting Person's continued service on each such vesting date.</footnote>
        <footnote id="F2">This option was granted in connection with the Reporting Person's promotion within the Company. The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following November 4, 2025, subject to the Reporting Person's continued service on each such vesting date.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Elizabeth Rozek</signatureName>
        <signatureDate>2025-11-06</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
